Lopinavir ritonavir

Revision as of 03:22, 10 January 2014 by Mohamed Moubarak (talk | contribs) (→‎Overview)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Lopinavir ritonavir
KALETRA ® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

For patient information, click here.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamed Moubarak, M.D. [2]

Overview

Lopinavir/ritonavir (INNs) is a fixed dose combination drug for the treatment of HIV infection. It combines lopinavir (not available as a single drug) with a sub-therapeutic dose of ritonavir (trade name Norvir) into a fixed-dose pill.

The combination is marketed by Abbott as Kaletra (high-income countries) and Aluvia (low-income countries), as a component of combination therapy to treat HIV/AIDS. The Kaletra formulation has also been used successfully as monotherapy in some studies.[1]

As of 2006, lopinavir/ritonavir forms part of the preferred combination for first-line therapy recommended by the United States Department of Health and Human Services (DHHS).[2] It is available as capsules, tablets and oral solution.

Category

Antiretroviral

US Brand Names

KALETRA®

FDA Package Insert

Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Dosage and Administration | How Supplied | Labels and Packages

Mechanism of Action

Lopinavir is an antiviral drug. As co-formulated in KALETRA, ritonavir inhibits the CYP3A-mediated metabolism of lopinavir, thereby providing increased plasma levels of lopinavir.[3]

References

  1. Gadd, Christopher; Alcorn, Keith (18 August 2006). "Kaletra monotherapy as effective as triple therapy for at least 18 months". aidsmap.com. aidsmap. Retrieved 24 June 2011.
  2. DHHS panel. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (May 4, 2006). (Available for download from AIDSInfo)
  3. "KALETRA (LOPINAVIR AND RITONAVIR) TABLET, FILM COATED KALETRA (LOPINAVIR AND RITONAVIR) SOLUTION [ABBVIE INC.]". Text " accessdate" ignored (help)